Trial Simulation, Drug Selection To Be Focus Of US FDA's Drug Development Modeling Pilot
Executive Summary
Meeting requests from sponsors that focus on safety prediction will also be prioritized.
You may also be interested in...
Work Presses On To Harmonize Global Expectations On Using Modeling & Simulation
The level at which model-based analyses is integrated into regulatory decision-making can vary between regulatory agencies, from application to application and within agencies for similar submissions, leading to missed opportunities, says the International Council for Harmonisation.
PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
Complex Innovative Designs Pilot Likely Satisfies Industry's Disclosure Worries
US FDA says sponsors generally won’t need to publicly disclose company or product if selected for pilot, but rather elements about design of their complex trial.